fda warning letters compounded semaglutide november 2025 Why the Issued 30 to Telehealth Sites Marketing GLP-1s FDA Issues 30 Warning Letters

The impact of the circadian timing system on cardiovascular and metabolic function

Pre-restart assessment should include: Review of the reason for discontinuation and whether it has been adequately addressed Current weight and glycemic status (if diabetic) Assessment of gastrointestinal symptoms and any contraindications Medication reconciliation to identify potential drug interactions For patients taking insulin or sulfonylureas, consider dose reductions to prevent hypoglycemia For women of childbearing potential using oral contraceptives, recommend backup contraception for 4 weeks after restarting and after each dose increase Discussion of realistic expectations and commitment to continued treatment Patient counseling is essential

A new article in the American Journal of Preventive Cardiology outlines how clinicians can counsel patients who have reservations about taking GLP-1s.[1] "After decades of development and extensive clinical use, GLP-1 RAs have proven to be safe and effective therapies for cardiometabolic disease

its about fueling your body with nutrient-dense foods and finding movement you enjoy

Tm hiu thm: Vitamin B6 c tc dng g